Nektar Therapeutics (NKTR) Misses Q1 EPS by 7c, Revenues Beat
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $60.98 +0.10%
EPS Growth %: +26.6%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +26.6%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.78), $0.07 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $50.57 million versus the consensus estimate of $47.64 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- John Rogers Jr. to leave Nike board after eight years of service
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Morgan Stanley Downgrades Melco Resorts (MLCO) to Equalweight
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
